爱沙尼亚宫颈癌高发病率与低筛查覆盖率背景下HPV疫苗接种的成本效果
研究采用马尔可夫队列模型评估爱沙尼亚12岁女孩二价、四价或九价HPV疫苗两剂次学校接种联合筛查的成本效果,疫苗覆盖率假设为70%。与单独筛查相比,接种的增量成本效果比分别为每质量调整生命年14007欧元(二价)、14067欧元(四价)和11633欧元(九价)。作者认为在爱沙尼亚可视为具有成本效果的干预。
要点
- 12岁女孩接种联合筛查较单独筛查的ICER为每QALY 14007欧元(二价)、14067欧元(四价)、11633欧元(九价)。
- 敏感性分析中ICER范围分别为5367-21711欧元、5142-21800欧元和4563-18142欧元。
- 成本效果最依赖疫苗价格和免疫持续时间,而非疫苗类型。
核心结论
- 在爱沙尼亚,12岁女孩接种HPV疫苗联合现行宫颈癌筛查可视为具有成本效果的干预。
- 将HPV疫苗纳入国家免疫规划预期可预防大量HPV感染、生殖器疣、癌前病变、HPV相关癌症和死亡。
- 尽管模型中ICER因疫苗类型略有差异,但总体落在相同范围内。
- HPV疫苗的成本效果最依赖于疫苗成本和疫苗免疫持续时间,而非疫苗类型。
研究设计与样本
- 采用HPV感染自然史的马尔可夫队列模型。
- 评估在国家级学校接种规划中对12岁女孩以两剂次接种二价、四价或九价疫苗的成本效果。
- 模型随访HPV感染自然进展至生殖器疣、癌前病变(CIN1-3)、宫颈癌、口咽癌、外阴癌、阴道癌和肛门癌。
- 疫苗覆盖率假设为70%。
- 时间跨度88年(至100岁),以涵盖所有终身疫苗接种成本和收益。
主要发现
- 与单独筛查相比,接种联合筛查的ICER为基础情景下每QALY 14007欧元(二价)、14067欧元(四价)和11633欧元(九价)。
- 敏感性分析中,ICER范围分别为5367-21711欧元(二价)、5142-21800欧元(四价)和4563-18142欧元(九价)。
- 结果对贴现率、疫苗接种方案、疫苗价格和宫颈癌筛查覆盖率的变化最为敏感。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Estonia has high cervical cancer incidence and low screening coverage. We modelled the impact of population-based bivalent, quadrivalent or nonavalent HPV vaccination alongside cervical cancer screening. METHODS: A Markov cohort model of the natural history of HPV infection was used to assess the cost-effectiveness of vaccinating a cohort of 12-year-old girls with bivalent, quadrivalent or nonavalent vaccine in two doses in a national, school-based vaccination programme. The model followed the natural progression of HPV infection into subsequent genital warts (GW); premalignant lesions (CIN1-3); cervical, oropharyngeal, vulvar, vaginal and anal cancer. Vaccine coverage was assumed to be 70%. A time horizon of 88years (up to 100years of age) was used to capture all lifetime vaccination costs and benefits. Costs and utilities were discounted using an annual discount rate of 5%. RESULTS: Vaccination of 12-year-old girls alongside screening compared to screening alone had an incremental cost-effectiveness ratio (ICER) of €14,007 (bivalent), €14,067 (quadrivalent) and €11,633 (nonavalent) per quality-adjusted life-year (QALY) in the base-case scenario and ranged between €5367-21,711, €5142-21,800 and €4563-18,142, respectively, in sensitivity analysis. The results were most sensitive to changes in discount rate, vaccination regimen, vaccine prices and cervical cancer screening coverage. CONCLUSION: Vaccination of 12-year-old girls alongside current cervical cancer screening can be considered a cost-effective intervention in Estonia. Adding HPV vaccination to the national immunisation schedule is expected to prevent a considerable number of HPV infections, genital warts, premalignant lesions, HPV related cancers and deaths. Although in our model ICERs varied slightly depending on the vaccine used, they generally fell within the same range. Cost-effectiveness of HPV vaccination was found to be most dependent on vaccine cost and duration of vaccine immunity, but not on the type of vaccine used.
引用
- Võrno T, Lutsar K, Uusküla A, et al. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage. Vaccine. 2017. PMID: 28899625. doi:10.1016/j.vaccine.2017.08.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。